



Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.
Mobile : 99099 28332
E-mail: info@bplindia.in, Web.: www.bplindia.in
CIN NO: L24231GJ1992PLC018237
(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Date: November 28, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Scrip Code: 541096

Dear Sir/Madam,

Sub: Completion of EU GMP inspection by Belgium's FAMPH at Innoxel Lifesciences Pvt. Ltd. Subsidiary Company of Bharat Parenterals Limited.

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that the **European Union Good Manufacturing Practice (EU GMP)** has conducted an inspection at our Subsidiary Company Namely Innoxel Lifesciences Pvt. Ltd. Company has successfully cleared **European Union Good Manufacturing Practice (EU GMP)** inspection at its manufacturing facility in Vadodara, Gujarat. The inspection was conducted from November 24, 2025 to November 28, 2025.

Please find the enclosed Company statement titled "**Innoxel Lifesciences Successfully Completes EU GMP Inspection by Belgium's FAMHP.**"

We request you to kindly take the same on record.

Thanking You,

For, **Bharat Parenterals Limited**

Sharmin Soni
Company Secretary & Compliance Officer
M. No: A75694



Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

PRESS RELEASE

Innoxel Lifesciences Successfully Completes EU GMP Inspection by Belgium's FAMHP.

28th November 2025

Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences, is pleased to announce the **successful completion of the European Union Good Manufacturing Practice (EU GMP) inspection** conducted by the **Federal Agency for Medicines and Health Products, Belgium (FAMHP)**.

The inspection was carried out at the company's manufacturing facility from **24th November 2025 to 28th November 2025**. The audit was completed with **zero critical and zero major observations**, reflecting the company's strong quality systems, robust manufacturing infrastructure, and strict adherence to global regulatory standards.

This milestone further strengthens the company's regulatory credentials following its earlier successful **USFDA inspection outcomes** and reinforces its position as a trusted partner in regulated international markets.

Management Commentary

Commenting on the development, the management said:

"Successfully completing the EU GMP inspection by the FAMHP, Belgium with zero critical and zero major observations is a testament to our teams' dedication to quality and compliance. This achievement enhances our ability to serve regulated markets and supports our long-term strategic growth objectives."

Bharat Parenterals and Innoxel Lifesciences remain committed to expanding their global footprint through continued investments in quality, systems, and regulatory excellence.
